Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

被引：0
作者：
Peter C. Taylor
Marc Feldmann
机构：
[1] Imperial College,Kennedy Institute of Rheumatology Division
来源：
Nature Reviews Rheumatology | 2009年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor (TNF) is expressed at high levels in synovial tissue from patients with RA. Through preclinical studies, animal model studies and human trials, this cytokine was the first to be fully validated as a therapeutic target for RA. Several approaches to blocking TNF have been developed, demonstrating considerable benefit in most of the patients treated.
引用
收藏
页码：578 / 582
页数：4
相关论文
共 92 条
[1]  
Brennan FM(1989)Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 244-247
[2]  
Chantry D(1995)Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-α antibody with the interleukin-1 receptor antagonist Eur. Cytokine Netw. 6 225-230
[3]  
Jackson A(1991)Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α Eur. J. Immunol. 21 2575-2579
[4]  
Maini R(1991)Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc. Natl Acad. Sci. USA 89 9784-9788
[5]  
Feldmann M(2000)Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group N. Engl. J. Med. 343 1594-1602
[6]  
Butler DM(1999)A trial of etanercept, a recombinant tumor necrosis factor receptor–Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 253-259
[7]  
Maini RN(2003)Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum. 48 35-45
[8]  
Feldmann M(2008)Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum. 58 3319-3329
[9]  
Brennan FM(2009)Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Ann. Rheum. Dis. 68 797-804
[10]  
Haworth C(2009)GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study Ann. Rheum. Dis. 68 789-796
12345678910